Healthcare stocks underperform S&P 500 for 3 consecutive months

Investor uncertainty over FDA leadership and unpredictable regulatory decisions will drive downward pressure on biotech and pharma stocks. Political jockeying and internal vacancies at the FDA reduce confidence in long-term policy stability.

Implied probability (Yes)

68%